29 m⁶A-RNA Methylation (Epitranscriptomic) Regulators Are Regulated in 41 Diseases including Atherosclerosis and Tumors Potentially via ROS Regulation – 102 Transcriptomic Dataset Analyses

Figure 6

The m⁶A-RNA methylation regulators (m⁶A-RMRs) were differentially expressed in several different organ failure diseases. (a) More m⁶A-RMRs were significantly increased and decreased in hepatitis B virus- (HBV-) associated acute liver failure (HBV-ALF) and hemodialysis diseases. The expression fold changes of IGF2BP1 and IGF2BP2 were higher, and the expression fold changes of ZC3H13 and YTHDF3 were lower in HBV-ALF. The expression fold changes of most m⁶A-RMRs were lower in whole blood of end-stage renal failure (ESRF) while the expression fold changes of some m⁶A-RMRs (WTAP, PCIF1, and EIF3A) were higher in PBMC of hemodialysis compared with healthy control. (b) Venn diagram showed that there were no shared upregulated or downregulated m⁶A-RMRs among these four studies. Some m⁶A-RMRs were decreased between organ failure diseases: YTHDC2 and FMR1 were shared between HF and HBV-ALF; METTL14, FTO, and YTHDF1 were shared between HBV-ALF and ESRF; G3BP1 was shared between HBV-ALF and ESRF. Note: the red marked genes are those that are up- or downregulated in different diseases (). Abbreviations: HBV-ALF: hepatitis B virus- (HBV-) associated acute liver failure; CKD: chronic kidney disease; ESRF: end-stage renal failure; FC: fold change; NA: not available (missing value).

(a)

(b)